Table 2 Type and number of grade 2 adverse events in the pre-erythrocytic phase: between day of injection (day 0) and day 5
Adverse event description | CHMI Groups | Total | |||||
|---|---|---|---|---|---|---|---|
Group 1 2,500 PfSPZ 10 µL × 2 IM | Group 2 2,500 PfSPZ 50 µL × 2 IM | Group 3 2,500 PfSPZ 250 µL × 2 IM | Group 4 3,200 PfSPZ 500 µL × 1 DVI | Group 5 25,000 PfSPZ 10 µL × 2 IM | Group 6 75,000 PfSPZ 10 µL × 2 IM | ||
Abdominal pain | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
Atopic dermatitis lesions | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
Common cold | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Diarrhoea | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Dysmenorrhoea | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
Dyspepsia | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
Headache | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
Muscle spasm | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
Total | 4 | 1 | 1 | 1 | 2 | 2 | 11 |